课题基金 / 基金详情

Biology of EGFR and P53 in esophageal epithelial cells

Biology of EGFR and P53 in esophageal epithelial cells
食管上皮细胞中 EGFR 和 P53 的生物学
批准号:
7219886
负责人:
CARMEN Z MICHAYLIRA
金额:
$4.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2009-11-30

项目摘要

项目成果

CARMEN Z MICHAYLIRA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):食管癌是一种高度侵袭性的恶性肿瘤,是全球第六大癌症死亡原因。食管癌主要有两种类型:食管鳞状细胞癌(ESCC)和腺癌。本项目的重点是阐明食管鳞状上皮恶性转化早期事件的分子机制。表皮生长因子受体(EGFR)过表达和p53突变是食管鳞状细胞癌癌前期常见的遗传改变。然而,EGFR和突变p53在食管癌发生中的分子基础仍不清楚。为此,将在体外和体内确定EGFR过表达和p53突变的生物学作用和功能后果。我们提出的研究将使用食管上皮细胞和食管中靶向过表达EGFR和突变p53的小鼠模型来确定这些遗传改变在ESCC中的作用。我们的基本假设是,配体激活EGFR诱导细胞反应,促进基底细胞间室的过度增殖,并诱导这些细胞迁移到基底上细胞间室,而不致力于分化。尽管这些过程是必要的,但它们不足以导致癌症,因此,其他遗传事件,如p53突变,是必需的。这一假设将通过以下相关的具体目的来实现:目的1:评估食管上皮细胞中EGFR过表达和p53失活结合的后果。过表达EGFR和四种不同突变p53s的食管上皮细胞将在单层、三维基质和器官型培养中培养。研究将测试对增殖、迁移和入侵能力的影响,以及对关键信号分子的影响。目的2:利用食管中表达EGFR和突变型p53的小鼠(cre-lox系统),了解EGFR和突变型p53协同作用在体内的作用。研究将试图通过在食管中特异性表达人EGFR和突变型p53来产生两种新的ESCC体内模型。去年,美国确诊的食管癌新病例超过14000例。据估计,90%以上的确诊患者将死于疾病。这些研究旨在为EGFR过表达和p53失活在ESCC发展中的生物学作用提供新的见解。最终,这些可能转化为更新的诊断和治疗方式。
英文摘要
DESCRIPTION (provided by applicant): Esophageal cancer is a highly aggressive malignancy and is the sixth leading cause of cancer death worldwide. There are two main types of esophageal cancer, esophageal squamous cell carcinoma (ESCC) and adenocarcinoma. This project focuses upon the elucidation of molecular mechanisms underlying early events in malignant transformation in the esophageal squamous epithelium. Epidermal growth factor receptor (EGFR) overexpression and p53 mutation are frequent genetic alterations in the premalignant stages of esophageal squamous cell carcinogenesis. Yet, the molecular basis for EGFR's and mutated p53's contributions to esophageal carcinogenesis remains unclear. To that end, the biological roles and functional consequences of EGFR overexpression and p53 mutation will be determined in vitro and in vivo. Our proposed studies will use esophageal epithelial cells and mouse models with targeted overexpresssion of EGFR and mutant p53 in the esophagus to determine the role of these genetic alterations in ESCC. Our fundamental hypothesis is that ligand activation of EGFR induces cellular responses that facilitate hyperproliferation in the basal cell compartment and induction of migration of such cells into the suprabasal compartment without commitment to differentiation. Although, these processes are necessary they are not sufficient to cause cancer, and thus, other genetic events, such as p53 mutation, are required. This hypothesis will be pursued by the following interrelated Specific Aims: Aim 1: To assess the consequences of the combination of EGFR overexpression and p53 inactivation in esophageal epithelial cells. Esophageal epithelial cells overexpressing EGFR and four diffent mutant p53s will be characterized when grown in monolayer, and three-dimesional Matrigel and organotypic culture. Studies will test effects on proliferation, migration and invasion capabilities as well as effects on key signaling molecules. Aim 2: To understand the in vivo roles of the cooperation of EGFR and mutant p53 using mice (cre-lox system) expressing EGFR and mutant p53 in the esophagus. Studies will attempt to generate two novel in vivo models of ESCC by expressing human EGFR and mutant p53 specifically in the esophagus. Over 14,000 new cases of esophageal cancer were diagnosed in the United States last year. It is estimated that more than 90% of those diagnosed will die of their disease. The proposed studies aim to provide novel insights into the biological roles of EGFR overexpression and p53 inactivation in the development of ESCC. Ultimately, these may translate into newer diagnostic and therapeutic modalities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biology of EGFR and P53 in esophageal epithelial cells
  • 批准号:
    7324095
  • 项目类别:
  • 资助金额:
    $4.88万
  • 财政年份:
    2006
  • 负责人:
    CARMEN Z MICHAYLIRA
  • 依托单位:
海外基金